Curespec Overview
Curespec offers a medical device solution that uses noninvasive shockwave therapy for the treatment of hypertension and chronic kidney disease (CKD). The company’s technology is designed to generate new blood vessels and restore function to damaged tissue. Curespec’s first market-ready product, Nephrospec, is a safe, low-intensity, noninvasive shockwave device delivering electro-hydraulic acoustic therapy (eHAT) intended for the interrelated treatment of hypertension and CKD. Designed to save up to 80% of costs while reducing suffering and needless loss of life, Nephrospec can improve kidney function in weeks, delay onset of dialysis with outpatient treatment, and function as a complementary solution to optimal medical care for hypertension and CKD. Curespec has obtained CE and AMAR approval in Europe and Israel respectively.
Cumulative Funding Raised Over Time ($)
$1.0MJan 2023
$7.4MJun 2020
Latest News
growth-positive
Startup aiming to keep kidney patients off dialysis - ISRAEL21c
Israeli medical device company Curespec has developed a device, Nephrospec, which it claims can postpone dialysis treatment for stage three and four chronic kidney disease (CKD) patients by up to 12 months. The company is now conducting clinical trials to prove the devices efficacy. Nephrospec is also being promoted as an effective treatment for hypertension. The company has raised over $1 million from private investors, received a $3.4 million grant from the National Institutes of Health, and an initial $3 million investment from Medispec. It is now aiming to raise $10 million in a seed funding round to complete its clinical trials.
InvestmentExpand
growth-positive
Meet the man who is making medical devices for the masses
Avner Spector, founder of Medispec and Curespec, has been improving lives with his medical equipment designs. Medispec, founded in 1992, operates in 44 countries and was the first to apply electro-Hydraulic Acoustic Therapy (eHAT) to sexual health indications. Curespecs first product, Nephrospec, uses eHAT to treat chronic kidney disease (CKD) by promoting new blood vessel formation and restoring damaged tissue function. The treatment is painless, and improvement is seen after only six sessions over a three-week period. Spector believes the technology will soon be proven effective for other kidney diseases and even kidney transplants.
CustomersExpand
growth-positive
הסטארט-אפ הישראלי שמתקן את הכליות שלכם וחוסך מיליארדים למערכת הבריאות | כלכליסט
Curespec, an Israeli startup, is pioneering a unique low-intensity shockwave technology to delay dialysis needs and improve kidney function, potentially reducing healthcare costs significantly. The company is currently seeking investors to expand its operations globally. Clinical studies in Japan, the US, and Israel have shown promising results, including reduced treatment times and improved kidney function, with no significant adverse events reported. The NIH has recognized the technologys importance, funding initial research with $3.4 million. Curespecs device has received CE approval for Europe and is expected to be marketed soon. In January 2023, Curespec won a Chinese innovation competition, attracting interest from Fosun. The company is poised for substantial growth, with opportunities for investors to join.
Investment
growth-positive
N12 - גלי קול שדוחים את הטיפול בדיאליזה: התקווה החדשה של חולי...
Israeli start-up Curespec has developed a device called NephroSpec that uses sound waves to stimulate the growth of new blood vessels in the kidneys, potentially delaying the need for dialysis in patients with chronic kidney disease. The device has undergone successful trials in Israel, Japan, and the Philippines, and has received approval from the European Union and Israels Ministry of Health. Curespec, which was founded in December 2020, has raised $3.4 million from the National Institutes of Health and $500,000 from private investors. The company is now seeking to raise an additional $2 million at a valuation of $14 million.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $7.4M |
| Last funding | $1M |
| Stage | A |
| Rounds | 2 |
| Investors | 0 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | www.curespec.info |
Locations
HaTa'asiya Street 40, Yehud-Monosson, Israel
Photos & Videos
2 item(s)
Curespec Business
Business models
B2C, B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCore Technology
—Tags (13)
chronic-diseasetissue-regenerationcardiologypain-reliefhospitalsnephrologyblood-pressurenon-invasivedialysisclinicstreatmentsmedical-devicesmedical-technologiesGeographic Markets
EuropeUnited StatesSoutheast AsiaCentral AmericaCurespec Financials
$7.4M
Total funding
Undisclosed
Capital raised
$1M
Last funding
A
Funding stage
2
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
$1.0MJan 2023
$7.4MJun 2020
Private Equity Funding
A Round
Jan 2023
$1M
Seed
Jun 2020
$6.4M
Curespec Lifecycle
Cumulative Funding Raised Over Time
$1.0MJan 2023
$7.4MJun 2020
All Events
A Round
Jan 2023
$1M
Seed
Jun 2020
$6.4M
Curespec News
4 articles
growth-positive
Startup aiming to keep kidney patients off dialysis - ISRAEL21c
Israeli medical device company Curespec has developed a device, Nephrospec, which it claims can postpone dialysis treatment for stage three and four chronic kidney disease (CKD) patients by up to 12 months. The company is now conducting clinical trials to prove the devices efficacy. Nephrospec is also being promoted as an effective treatment for hypertension. The company has raised over $1 million from private investors, received a $3.4 million grant from the National Institutes of Health, and an initial $3 million investment from Medispec. It is now aiming to raise $10 million in a seed funding round to complete its clinical trials.
InvestmentExpand
growth-positive
Meet the man who is making medical devices for the masses
Avner Spector, founder of Medispec and Curespec, has been improving lives with his medical equipment designs. Medispec, founded in 1992, operates in 44 countries and was the first to apply electro-Hydraulic Acoustic Therapy (eHAT) to sexual health indications. Curespecs first product, Nephrospec, uses eHAT to treat chronic kidney disease (CKD) by promoting new blood vessel formation and restoring damaged tissue function. The treatment is painless, and improvement is seen after only six sessions over a three-week period. Spector believes the technology will soon be proven effective for other kidney diseases and even kidney transplants.
CustomersExpand
growth-positive
הסטארט-אפ הישראלי שמתקן את הכליות שלכם וחוסך מיליארדים למערכת הבריאות | כלכליסט
Curespec, an Israeli startup, is pioneering a unique low-intensity shockwave technology to delay dialysis needs and improve kidney function, potentially reducing healthcare costs significantly. The company is currently seeking investors to expand its operations globally. Clinical studies in Japan, the US, and Israel have shown promising results, including reduced treatment times and improved kidney function, with no significant adverse events reported. The NIH has recognized the technologys importance, funding initial research with $3.4 million. Curespecs device has received CE approval for Europe and is expected to be marketed soon. In January 2023, Curespec won a Chinese innovation competition, attracting interest from Fosun. The company is poised for substantial growth, with opportunities for investors to join.
Investment
growth-positive
N12 - גלי קול שדוחים את הטיפול בדיאליזה: התקווה החדשה של חולי...
Israeli start-up Curespec has developed a device called NephroSpec that uses sound waves to stimulate the growth of new blood vessels in the kidneys, potentially delaying the need for dialysis in patients with chronic kidney disease. The device has undergone successful trials in Israel, Japan, and the Philippines, and has received approval from the European Union and Israels Ministry of Health. Curespec, which was founded in December 2020, has raised $3.4 million from the National Institutes of Health and $500,000 from private investors. The company is now seeking to raise an additional $2 million at a valuation of $14 million.
Investment
Curespec Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 9 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
Curespec Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 516299351 |
| Phone | 0555613011 |
| Creator | Igal Barboy |
| Creator email | igalb@medispec-int.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-09-27T00:00:00.000Z |
| Created | 2021-03-01T00:00:00.000Z |
| Claimed | Yes |